Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent.
Radmir R RakhimovAleksandr V SultanbaevAdel A IzmailovKonstantin V MenshikovVadim M ZabelinAlbert A IzmailovGulshat R GilyazovaSvetlana M IzmailovaKsenia S BakhtiyarovaIzmailova AngelinaPublished in: Current pharmaceutical design (2023)
In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.